Articles by Daniel Marsh
Target Stock Plunges 3.8% as $25 Costume Backlash Erodes $2.9B in Value
Target shares dropped 3.8% after a $25 Halloween costume backlash erased $2.9B in market value. The retailer pulled the product and apologized.
Hyperscale Data Tumbles 17% Post Reverse Split, GPU Units Slip Below $1
Hyperscale Data shares dropped 17.3% to $0.3869 after a 1-for-5 reverse split, leaving GPU units 61% below $1. Bitcoin holdings and data-center expansion plans weigh on valuation.
Tenax Surges 28% on $1.81M Insider Buy Ahead of Trial Data
Tenax shares surged 27.84% to $2.37 after a director bought $1.81M of stock. Investors await further LEVEL trial data on August 29.
Oklo Surges 11.5% on Canada Uranium Threat, Adding $850M in Value
Oklo (NYSE:OKLO) climbed 11.5% to $44.26 after Ontario's premier suggested uranium could be used as leverage in the U.S.-Canada trade dispute, adding roughly $850 million to its market value.
TNL Mediagene Jumps 53% on Nasdaq Reprieve, Still Faces Steep Compliance Climb
TNL Mediagene shares soared 53% after Nasdaq granted a conditional listing extension, though the stock still needs a 64.6% gain to meet the $1 minimum bid price.
Fluence Energy Rebounds as UBS Sees Guidance Cut as a Floor
Fluence Energy shares gained 4.7% after UBS upgraded the stock to Neutral, citing the guidance reduction as a floor, not a demand loss.
707 Cayman Stock Soars 58% on $10.25M Deal Financing
707 Cayman shares surged 57.85% to $6.03 after a $10.25M financing plan for the acquisition of Crucial Innovation, despite the deal being non-binding and target financials undisclosed.
ParaZero Soars 29% on First US Federal DefendAir Order
ParaZero shares surged 29% after a US federal agency placed its first DefendAir order, though the undisclosed value leaves revenue impact unclear.
RUM Group Surges 12% on $13.7B GPU Deal, But Dilution Risks Loom
RUM Group shares climbed 12% on a $13.7B GPU deal, but a 50.8M-share warrant and unfunded project raise dilution and financing risks.
CRISPR Therapeutics Stock Jumps Ahead of Key CTX310 Data
CRISPR Therapeutics shares climbed 5.8% to $60.38 ahead of CTX310 results due Aug 28. Analysts maintain an $80 target, citing potential as a one-time therapy.
Richtech Robotics Stock Soars 17% on $12M Buyback Amid Heavy Dilution
Richtech Robotics shares surged 17% on a $12M buyback authorization, but the program covers only a fraction of recent dilution as share count has doubled in a year.
Bloom Energy Stock Soars on Pelosi Trade Disclosure
Bloom Energy (BE) shares climbed 5.4% after a Pelosi household disclosure, boosting market value by $3.3B. Q2 revenue surged 165.5% to $1.07B, with raised guidance.